Dr. Collins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
121 Sotoyome St
Santa Rosa, CA 95405Phone+1 707-546-4062Fax+1 707-525-4071
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1992 - 1995
Johns Hopkins UniversityResidency, Internal Medicine, 1988 - 1991- Johns Hopkins University School of MedicineClass of 1988
Certifications & Licensure
CA State Medical License 1992 - 2026- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 72 citationsBemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 s...Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, Shukui Qin, Kensei Yamaguchi
The Lancet. Oncology. 2022-11-01 - 2 citationsCovariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.Hong Xiang, Lucy Liu, Yuying Gao, Ago Ahene, Helen Collins
Cancer Chemotherapy and Pharmacology. 2021-08-12 - 5 citationsPopulation pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trialHong Xiang, Lucy Liu, Yuying Gao, Ago Ahene, Monica Macal
Cancer Chemotherapy and Pharmacology. 2020-09-23
Press Mentions
- Prime Time for Five Prime as Amgen Snaps up This Once-Moribund Biotech for $1.9B and Its Phoenix-from-the-Flames Cancer AssetMarch 4th, 2021
Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ CancersJanuary 15th, 2021- Five Prime Shares Triple in Value as Firm Meets All 3 Primary Endpoints in Phase 2 Gastric and GEJ Cancer TrialNovember 13th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
